The current developments of the new biological drugs targeting interleukin 5 (IL-5) and IL-5 receptor allowed to expand the\ntreatment options for severe hypereosinophilic asthma. Clinicians will then be able to choose between antibodies targeting either\ncirculating IL-5 or its receptor expressed on eosinophils and basophils.The available clinical trials consistently reported favorable\nresults about the reduction of exacerbations rate, improvement in quality of life, and sparing of the systemic steroid use, with a\nfavorable safety profile. Two of these new drugs are administered subcutaneously, mepolizumab every 4 weeks and benralizumab\nevery 8 weeks, whereas reslizumab is given intravenously monthly on a weigh-based dose. In the future, the research actions will be\ninvolved in the identification of a single biomarker ormultiple biomarkers for the optimal choice of biological agents to be properly\nprescribed.
Loading....